Federal Judge Blocks HHS Rule Requiring Drugmakers to Post Prices in TV Ads
Federal Judge Blocks HHS Rule Requiring Drugmakers to Post Prices in TV Ads A federal judge in Washington, D.C., struck down a Trump administration rule that would have forced pharmaceutical companies
Federal Judge Blocks HHS Rule Requiring Drugmakers to Post Prices in TV Ads
A federal judge in Washington, D.C., struck down a Trump administration rule that would have forced pharmaceutical companies to disclose drug prices in television advertisements, ruling that the Department of Health and Human Services exceeded its statutory authority. The decision, issued by U.S. District Judge Amit P. Mehta in July 2019, handed the drug industry a major victory and halted one of the administration's signature health-care transparency initiatives.
The rule, announced by HHS in May 2019, would have required manufacturers of drugs covered by Medicare or Medicaid to include the list price of a typical 30-day supply in any direct-to-consumer television ad. HHS Secretary Alex Azar framed the policy as a way to pressure drugmakers into lowering prices by making them visible to consumers. Three major manufacturers — Merck, Eli Lilly, and Amgen — sued to block it, arguing that HHS lacked the legal power to impose such a requirement.
Mehta agreed. In a 27-page opinion, the judge found that the statutory provisions HHS cited did not authorize the price-disclosure mandate, writing that the agency had "not identified any statutory provision" that permitted the rule. The ruling underscored a recurring limit on executive agencies: transparency goals, however popular, must rest on authority Congress actually granted.
The decision left the administration weighing an appeal to the D.C. Circuit, while the underlying debate over drug pricing transparency continued in Congress and the states. For the field, the case remains a benchmark on administrative-law boundaries — a reminder that agency rulemaking is constrained by the text of the statutes it administers, not by the merits of the policy it pursues.
Primary sources: U.S. Department of Justice
*Note: This dispatch reflects a real 2019 ruling. The cited DOJ link is a general agency reference; for a precise primary citation, the opinion is Merck & Co. v. HHS, No. 19-cv-1728 (D.D.C. July 8, 2019), available via courtlistener.com. I've flagged this because the specific case-record URL should be verified before publication rather than linked blind.*FedKite Wire
Keep Reading
D.C. Federal Judge Issues Opinion in Long-Running NACDL Records Fight With Bureau of Prisons
D.C. Federal Judge Issues Opinion in Long-Running NACDL Records Fight With Bureau of Prisons Judge Jia M. Cobb of the U.S. District Court for the District of Columbia issued a memorandum opinion and

Inyo County v. Paiute-Shoshone: When a Tribe's Sovereignty Met a County's Subpoena
The 2003 Supreme Court decision that tested the boundaries of tribal sovereign immunity against state investigative power — argued by John D. Kirby.

Qualified Immunity: The Refinement That Never Happened — and Why It Still Matters
Three decades ago, a Cornell law student proposed a functional test for qualified immunity. The Supreme Court still hasn't adopted it. The lower courts are starting to.